Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
25.7M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
21.2M
-
Shares change
-
+592K
-
Total reported value, excl. options
-
$272M
-
Value change
-
-$49.2M
-
Put/Call ratio
-
3.81
-
Number of buys
-
53
-
Number of sells
-
-44
-
Price
-
$12.86
Significant Holders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) as of Q2 2024
122 filings reported holding TRML - Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share as of Q2 2024.
Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.2M shares
of 25.7M outstanding shares and own 82.42% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (2.54M shares), Avoro Capital Advisors LLC (2.22M shares), BlackRock Inc. (1.72M shares), Blue Owl Capital Holdings LP (1.72M shares), TCG Crossover Management, LLC (1.48M shares), JENNISON ASSOCIATES LLC (1.13M shares), VANGUARD GROUP INC (1.05M shares), Qiming U.S. Ventures Management, LLC (742K shares), RTW INVESTMENTS, LP (742K shares), and QVT Financial LP (711K shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.